AVZO-021

AVZO-021 is a small-molecule drug developed by Avenzo Therapeutics. Its target is HER2 (the sponsor names CDK2). The sponsor states: AVZO-021 is a highly potent and selective oral CDK2 inhibitor targeting the cyclin E-CDK2 pathway, which becomes hyperactivated as a resistance mechanism to CDK4/6 inhibitors in HR+/HER2- breast cancer and other CCNE1-amplified solid tumours. ClinicalTrials.gov describes the intervention as: AVZO-021 is an oral selective CDK2 inhibitor. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer, ovarian cancer, endometrial cancer and triple-negative breast cancer. The largest, NCT05867251, plans to enrol 430 participants with primary completion expected 2028-01-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.